Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Bressac

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
The Journal of Urology|February 25, 1998
p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumorsF Pages, T A Flam, A Vieillefond, et al.
American Journal of Human Genetics|June 28, 2000
A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone familiesP Ciotti, J P Struewing, M Mantelli, et al.
British Journal of Cancer|August 1, 1996
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenograftsG Vassal, M J Terrier-Lacombe, M C Bissery, et al.
Journal of Medical Genetics|May 31, 2008
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS familiesG Bougeard, R Sesboüé, S Baert-Desurmont, et al.
Cancer Research|May 1, 1998
Mutations at BRCA1: the medullary breast carcinoma revisitedF Eisinger, J Jacquemier, C Charpin, et al.
British Journal of Cancer|March 25, 2000
Extensive molecular screening for hereditary non-polyposis colorectal cancerB Dieumegard, S Grandjouan, J C Sabourin, et al.
Familial Cancer|September 16, 2010
Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanomaB Buecher, M Gauthier-Villars, L Desjardins, et al.
Genes, Chromosomes & Cancer|October 2, 2001
Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effectS Auroy, M F Avril, A Chompret, et al.
The Journal of Endocrinology|August 9, 2003
Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumoursV V Vax, R Bibi, S Diaz-Cano, et al.
Human Mutation|June 1, 2001
The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcriptA Vega, B Campos, B Bressac-De-Paillerets, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
The Journal of Urology|February 25, 1998
p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumorsF Pages, T A Flam, A Vieillefond, et al.
American Journal of Human Genetics|June 28, 2000
A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone familiesP Ciotti, J P Struewing, M Mantelli, et al.
British Journal of Cancer|August 1, 1996
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenograftsG Vassal, M J Terrier-Lacombe, M C Bissery, et al.
Journal of Medical Genetics|May 31, 2008
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS familiesG Bougeard, R Sesboüé, S Baert-Desurmont, et al.
Cancer Research|May 1, 1998
Mutations at BRCA1: the medullary breast carcinoma revisitedF Eisinger, J Jacquemier, C Charpin, et al.
British Journal of Cancer|March 25, 2000
Extensive molecular screening for hereditary non-polyposis colorectal cancerB Dieumegard, S Grandjouan, J C Sabourin, et al.
Familial Cancer|September 16, 2010
Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanomaB Buecher, M Gauthier-Villars, L Desjardins, et al.
Genes, Chromosomes & Cancer|October 2, 2001
Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effectS Auroy, M F Avril, A Chompret, et al.
The Journal of Endocrinology|August 9, 2003
Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumoursV V Vax, R Bibi, S Diaz-Cano, et al.
Human Mutation|June 1, 2001
The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcriptA Vega, B Campos, B Bressac-De-Paillerets, et al.
Pageof 7